Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 12/20 | 0.59 |
| ▸ | FAAH | O00519 | 5/20 | 0.59 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL17644778 | 0.98 | MGLL (0.58) | MGLLFAAHDDAH1NPSR1HSP90AA1 | |
| Hydrazine SCHEMBL27822007 | 0.87 | MGLL (0.56) | MGLLFAAHDDAH1NPSR1HSP90AA1 | |
| SCHEMBL514697 | 0.87 | MGLL (0.59) | MGLLFAAHDDAH1NPSR1HSP90AA1 | |
| Hydrochloric Acid SCHEMBL28737900 | 0.85 | MGLL (0.58) | MGLLFAAHDDAH1NPSR1HSP90AA1 | |
| SCHEMBL12657331 | 0.85 | MGLL (0.58) | MGLLFAAHDDAH1NPSR1HSP90AA1 | |
| SCHEMBL12683541 | 0.85 | MGLL (0.62) | MGLLFAAHDDAH1NPSR1HSP90AA1 | |
| SCHEMBL44044 | 0.84 | MGLL (0.54) | MGLLFAAHDDAH1NPSR1HSP90AA1 | |
| SCHEMBL8090506 | 0.84 | MGLL (0.56) | MGLLFAAHDDAH1NPSR1HSP90AA1 | |
| SCHEMBL27951835 | 0.84 | MGLL (0.73) | MGLLFAAHDDAH1NPSR1HSP90AA1 | |
| Phosphorylethanolamine SCHEMBL2267497 | 0.83 | MGLL (0.44) | MGLLFAAHDDAH1NPSR1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| WO-2025049959-A9 | GENE EDITING SYSTEMS, COMPOSITIONS, AND METHODS FOR TREATMENT OF VEXAS SYNDROME | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025049959-A2 | GENE EDITING SYSTEMS, COMPOSITIONS, AND METHODS FOR TREATMENT OF VEXAS SYNDROME | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-03-06 | — | — | WO | claimed |
| WO-2024238828-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2024-11-21 | — | — | WO | claimed |
| CN-114302741-A | Compositions and methods for treating autoimmune disorders | 密执安大学评议会 | 2022-04-08 | — | — | CN | claimed |
| WO-2016154542-A2 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-09-29 | — | — | WO | claimed |
| EP-1711163-A2 | DISPERSIONS PREPARED BY USE OF SELF-STABILIZING AGENTS | BAXTER INTERNATIONAL INC. (US) | 2006-10-18 | — | — | EP | claimed |
| EP-1605914-A1 | METHOD FOR PREPARING SMALL PARTICLES | BAXTER INTERNATIONAL INC. (US) | 2005-12-21 | — | — | EP | claimed |
| US-20050196416-A1 | Dispersions prepared by use of self-stabilizing agents | BAXTER HEALTHCARE S.A. (CH) | 2005-09-08 | — | — | US | claimed |
| WO-2005077337-A2 | DISPERSIONS PREPARED BY USE OF SELF-STABILIZING AGENTS | BAXTER INTERNATIONAL INC. (US) | 2005-08-25 | — | — | WO | claimed |
| WO-2004082659-A1 | METHOD FOR PREPARING SMALL PARTICLES | BAXTER INTERNATIONAL INC. (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040022862-A1 | Method for preparing small particles | BAXTER INTERNATIONAL INC. | 2004-02-05 | — | — | US | claimed |
| EP-4712948-A2 | GENE EDITING SYSTEMS AND COMPOSITIONS FOR TREATMENT OF HEMOGLOBINOPATHIES AND METHODS OF USING THE SAME | Renagade Therapeutics Management Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-10 | — | — | US | disclosed |
| US-20260062700-A1 | ENGINEERED RETRONS AND METHODS OF USE | RENAGADE THERAPEUTICS MAN INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| WO-2004017907-A2 | BLOOD CLOT-TARGETED NANOPARTICLES | BARNES-JEWISH HOSPITAL (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20040022862-A1 | Method for preparing small particles | BAXTER INTERNATIONAL INC. | 2004-02-05 | — | — | US | disclosed |
| EP-0968223-A1 | BIOCONJUGATION OF MACROMOLECULES | Proligo L.L.C. (US) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998030575-A1 | BIOCONJUGATION OF MACROMOLECULES | PROLIGO LLC (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062700-A1 | ENGINEERED RETRONS AND METHODS OF USE | NSUN3, RNASEH1, TRMT1L | MGLL 4122/4885FAAH 3685/4885DDAH1 2346/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | MGLL 28/4885FAAH 2196/4885DDAH1 3308/4885 |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | EXOSC10, PLTP, EXOSC9 | MGLL 892/4885FAAH 1698/4885DDAH1 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.